- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
 |
7436-22-8
CH6ClN
70.54
99.5% min (Isotopic Enrichment)
232-234
White solid
Psoriasis
Deucravacitinib
11/7/2033 (Deucravacitinib)
tyrosine kinase 2
N
5 kg
2018
ISO 9001
Supply Chain
Based on the proriasis market analysis, the 2023 demand for this intermediate trideuteriomethanamine;hydrochloride (CAS No. 7436-22-8) was esimated to range from 0.81 Kg to 4.45 Kg, depending on the specific route. Considering the deeper market penetration and the completion of Deucravacitinib clinical trials on other diseases, the demand is to grow.
As of July 29, 2024, there are 76 potential suppliers manufacturing Deucravacitinib intermediate trideuteriomethanamine;hydrochloride (CAS No. 7436-22-8), including 56 factories and 18 labs, among which:
- The 25th percentile has an average registered capital of 1 million CNY;
- The 50th percentile has an average registerd capital of 5 million CNY;
- The 75th percentile has an average registered capital of 10.14 million CNY.
Feeling overwhelmed? Contact Unibest if you need us to quality-check other sources to strengthen your supply chain or to find a tailored solution for your specific procurement request.
Usage in Deucravacitinib Analysis
Deucravacitinib, CAS No. 1609392-27-9, is a deuterated compound, and structurally speaking, four scaffolds can be identified:
- a benzene - triazole scaffold (scaffold A)
- a deuterated pyridazine (scaffold B + scaffold C)
- a three membered ring (scaffold D)
This compound, trideuteriomethanamine;hydrochloride, CAS No. 7436-22-8, is a deuterated compound and it is the deuteration source that contributes to the pyridazine scaffold of Deucravacitinib as shown below. If your facility is able to carry out deuteration step, then this intermediate is necessary for Deucravacitinib API synthesis.
The amine group on this Deucravacitinib intermediate is to react with the scaffold B (CAS No. 1442437-21-9) in the midway throughout the synthesis or at the late stages when other scaffolds have been conjugated together such as CAS No. 2245111-19-5 and CAS No. 2761695-60-5. It is the source of deuterium.
Zhuang, L. et al. Tyrosine Kinase 2 Inhibitors, Preparation Methods and Medicinal Uses Thereof. (2022).
Liu, J. et al. Tyrosine Kinase 2 (tyk2) Degradation Compounds and Methods of Use. (2022).
Greenwood, J. R. et al. Tyk2 Inhibitors and Uses Thereof. (2018).
Šagud, I. et al. Solid State Forms of Deucravacitinib, Deucravacitinib Hcl and Process for Preparation of Deucravacitinib and Intermediates. (2023).
Chen, K. et al. Process for the Preparation of 6-(cyclopropaneamido)-4-((2-Methoxy-3-(1-Methyl-1h-1,2,4-Triazol-3-Yl)phenyl)amino)-N-(methyl-D3)pyridazine-3-Carboxamide. (2018).
Li, P., Wang, P., Zhou, P., Zhao, X. & Wei, Q. Method for Synthesizing Deucravacitinib. (2024).
Wang, W. et al. Hydroxamate Compound, Preparation Method Therefor and Application Thereof. (2022).
Wrobleski, S. T. et al. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J. Med. Chem. 62, 8973–8995 (2019).
Chen, X. & Pang, Y. Heterocyclic Compounds for Inhibiting Tyk2 Activities. (2021).
Du, J. & Guo, L. Crystal Form of Pyridazine Derivative Free Base, and Preparation Method Therefor and Use Thereof. (2022).
Li, H., Li, Z., Zhou, J., Xu, J. & Zhang, Q.-Y. Compounds and Methods for Inhibiting Viral Replication and Methods of Treating and Preventing Flaviviral Infections. (2022).
Moslin, R. M., Weinstein, D. S., Wrobleski, S. T., Tokarski, J. S. & Kumar, A. AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES. (2014).
Brimert, T., Johnsson, R., Leffler, H., Nilsson, U. & Zetterberg, F. Alpha-D-Galactoside Inhibitors of Galectins. (2016).
